S'abonner

Tolerance induction with T cell–dependent protein antigens induces regulatory sialylated IgGs - 31/05/12

Doi : 10.1016/j.jaci.2012.02.037 
Carolin M. Oefner, MSc a, , André Winkler, MSc a, , Constanze Hess, PhD a, , Alexandra K. Lorenz, BSc a, Vivien Holecska, Tech a, Melanie Huxdorf, MSc a, Tim Schommartz, MSc b, Dominique Petzold, MSc b, c, Josephine Bitterling, Tech b, Anna-Lena Schoen, MSc b, Alexander D. Stoehr, PhD a, Dana Vu Van, MSc d, e, Yasemin Darcan-Nikolaisen, PhD f, Véronique Blanchard, PhD c, Inken Schmudde, MSc g, Yves Laumonnier, PhD g, Heike A. Ströver, MSc g, Ahmed N. Hegazy, MD h, i, Susanne Eiglmeier, PhD a, Carolin T. Schoen, PhD a, Maria M.M. Mertes, PhD a, Christoph Loddenkemper, MD j, k, Max Löhning, PhD h, Peter König, MD l, m, Arnd Petersen, PhD n, Elke O. Luger, PhD o, Mattias Collin, PhD p, Jörg Köhl, MD g, m, Andreas Hutloff, PhD d, e, Eckard Hamelmann, MD f, q, Markus Berger, PhD c, Hedda Wardemann, PhD r, Marc Ehlers, PhD a, b, m,
a Laboratory of Tolerance and Autoimmunity, German Rheumatism Research Center, Leibniz Institute, Berlin, Germany 
d Laboratory of Chronic Immune Reactions, German Rheumatism Research Center, Leibniz Institute, Berlin, Germany 
b Laboratory of Tolerance and Autoimmunity, Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany 
c Laboratory of Glycodesign and Glycoanalytics, Central Institute for Laboratory Medicine and Pathobiochemistry, Charité–University Medicine Berlin, Berlin, Germany 
f Department of Pediatric Pneumology and Immunology, Charité–University Medicine Berlin, Berlin, Germany 
h Laboratory of Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charité–University Medicine Berlin, Berlin, Germany 
i Department of Gastroenterology, Hepatology and Endocrinology, CCM, Charité–University Medicine Berlin, Berlin, Germany 
j Charité Research Center for ImmunoSciences/Institute of Pathology, Charité–University Medicine Berlin, Berlin, Germany 
e Molecular Immunology, Robert Koch Institute, Berlin, Germany 
g Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany 
l Institute of Anatomy, Center for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany 
k Institute of Pathology, Technical University Munich, Munich, Germany 
m Excellence Cluster of the German Research Foundation “Inflammation at Interfaces”, Lübeck, Germany 
n Division of Clinical and Molecular Allergology, Department of Pneumology, Research Center Borstel, Borstel, Germany 
o German Rheumatism Research Center, Leibniz Institute, Berlin, Germany 
p Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden 
q Children’s Hospital of Ruhr University, Bochum, Germany 
r Laboratory of Molecular Immunology, Max-Planck-Institute for Infection Biology, Berlin, Germany 

Corresponding author: Marc Ehlers, PhD, Institute for Systemic Inflammation Research, Laboratory of Tolerance and Autoimmunity, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.

Abstract

Background

Under inflammatory conditions, T cell–dependent (TD) protein antigens induce proinflammatory T- and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive.

Objective

It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction.

Methods

We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen–reactive serum IgGs after successful allergen-specific immunotherapy in patients.

Results

Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of ⍺2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate ⍺2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergic patients also induced sialylated allergen-specific IgGs.

Conclusions

Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity.

Le texte complet de cet article est disponible en PDF.

Key words : Tolerance, IgG antibodies, IgG sialylation, dendritic cells, allergy, asthma, antigen-specific immunotherapy, antigen-specific tolerance, antibody therapy

Abbreviations used : CFA, DC, DTH, IVIG, OVA, PC, SIT, TD, TNP


Plan


 Supported by the German Research Foundation (DFG) to M.E. (EH221-4 and 5), A.P., P.K., and J.K. (SFB/TR22 projects Z1, Z3 and A21). M.E. was a fellow of the Claussen-Simon-Foundation and supported by the Max Planck Institute for Infection Biology, Berlin, Germany. S.E. was supported by the International Max Planck Research School for Infectious Diseases and Immunology, Berlin, Germany. V.B. and M.B. were supported by the German Ministry of Research and Education (03IP511) and the Sonnefeld Foundation. M.C. was supported by grants from the Swedish Research Council (2010-57X-20240) and the Foundations of Wiberg, Österlund, and Hedlund; the Royal Physiographic Society; King Gustaf V’s Memorial Fund; and Hansa Medical AB.
 Disclosure of potential conflict of interest: C. Hess is an employee of Novo Nordisk AIS. M. Huxdorf is an employee of GlaxoSmithKline Research & Development China. Y. Darcan-Nicolaisen is an employee of Richter-Helm Biologics. C. T. Schoen is an employee of UCB Pharma GmbH. M. M. M. Mertes is an employee of Ku Patent. P. König has received research support from Deutsche Forschungsgemeinschaft. M. Collin has consulted for and received research support from Hansa Medical AB and has received research support from the Swedish Research Council, Wiberg’s Foundation, King Gustaf V’s Memorial Fund, Österlund’s Foundation, Hedlund’s Foundation, and the Royal Physiographic Society. M. Ehlers has received research support from the German Research Foundation. The rest of the authors declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 6

P. 1647 - juin 2012 Retour au numéro
Article précédent Article précédent
  • Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma
  • Chris J. Corrigan, Rahilya L. Napoli, Qiu Meng, Cailong Fang, Huifen Wu, Keri Tochiki, Victoria Reay, Tak H. Lee, Sun Ying
| Article suivant Article suivant
  • Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3–positive regulatory T cells
  • Amir H. Massoud, Julie Guay, Karim H. Shalaby, Eva Bjur, Aidan Ablona, Daniel Chan, Yasaman Nouhi, Christine T. McCusker, M. Walid Mourad, Ciriaco A. Piccirillo, Bruce D. Mazer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.